IDEMIA
16.6.2021 13:32:04 CEST | Business Wire | Press release
The Project Embarque + Seguro 100% Digital Boarding System, using the Brazilian government’s facial recognition, arrives this Tuesday (June 15) at the Congonhas Airport (SP). For the first time in the world, passengers on the air shuttle service between the capitals of São Paulo and Rio de Janeiro will participate in the simultaneous testing of this end-to-end technology without the need to present neither a boarding pass nor an identification document. The Project of the Ministry of Infrastructure, developed in partnership with Serpro and the Special Secretariat of Debureaucratization, Management and Digital Government of the Ministry of Economy, has already been tested at the airports of Florianópolis (SC), Salvador (BA), Santos Dumont (RJ) and Belo Horizonte (Confins).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005505/en/
After the approval of the pilot project, the Federal Government will move forward with actions to effectively implement the technology in major Brazilian airports. The technology aims at making the boarding process at airports more efficient, agile, and secure. "It is the first time that tests are carried out simultaneously in two of our airports, thus establishing, in an unprecedented way, a 100% biometric air shuttle between RJ / SP, which has the fifth-largest movement in the world", highlights the executive secretary of MInfra, Marcelo Sampaio.
Throughout the day, Azul Linhas Aéreas’s passengers travelling between Congonhas and Santos Dumont airports will be invited to try the biometric facial recognition technology to access both boarding area and aircraft at both terminals. "Embarque + Seguro combines biometric validation and data analysis, ensuring an accurate, agile and secure validation of the identity of passengers, who can thus travel with more comfort and tranquility. The solution complies with the General Data Protection Law (LGPD) and is premised on security in the processing of personal data against misuse or unauthorized use", emphasizes the president of Serpro, Gileno Barreto.
For the president of Infraero, Brigadier Paes de Barros, "the air shuttle’s Embarque + Seguro unites two essential items that streamline the boarding processes, which are safety and ease for the passenger and the entire civil aviation system".
According to the Director of Public Security & Identity (PSI) of IDEMIA in Brazil, Márcio Lambert, "Facial recognition is a global trend and the Project Embarque + Seguro, jointly carried out by Minfra and Serpro, shows that Brazil is on the right track to airport digitalization. IDEMIA’s technology is applied in the most modern airports around the world, such as Changi in Singapore, and offers a high level of security for passengers, airlines, and airport operators, as its algorithm is highly accurate, reaching a extremely high authenticity rate in the identification of individuals. IDEMIA is proud to participate in this project along with Brazil’s Federal Government and to enable the world’s first 100% end-to-end digitized boarding system in an executive air shuttle service".
"The latest Global Passengers Research conducted by the International Air Transport Association (IATA) says that 70% of interviewees are willing to share their biometry for identification purposes during the boarding process. Our global expertise contributes to meeting society’s need to fly again. This innovative project developed by the Federal Government allows travelers to enjoy a quieter, safer and more comfortable boarding experience and puts Brazil at the forefront of the digital transformation movement. IDEMIA as a global leader in augmented identity has the mission to facilitate the flow of passengers by creating the possibility to interact and travel in a more connected way. To participate in the first air shuttle with an end-to-end fully digitized boarding system, in both airports, is an important milestone in our history,” explains Rodrigo Costa, PSI business development director at IDEMIA LATAM.
The MFACE technology, developed by IDEMIA, captures facial biometrics in seconds, making the boarding process even more agile, avoiding queues and delays. The solution combines the convenience and security of data validation, respecting the privacy of passengers according to the GDPR, and ensures a more hygienic process by eliminating document and paper handling, thus avoiding the risk of contamination.
"The control of IDEMIA’s biometric system follows high-quality, reliability and safety standards and offers more agility and comfort to passengers, turning the airport operational process more intelligent, the airline passenger identification more accurate, and generates the security required by the government," adds Márcio Lambert.
How it works
When checking in at the airport, the passenger of Azul Linhas Aéreas is invited to participate in the project. If the passenger agrees, then a message is sent to the cell phone informed in the application, requesting authorization to obtain the passenger’s data, including the social security number and a photo. Upon consent, the airline attendant, using the application developed by Serpro for this purpose, performs the biometric validation of the citizen, comparing the data and the photo taken on the spot with the government databases.
After validated, the passenger is released to enter the departure hall and the aircraft passing through biometric control points, whose cameras perform the passenger’s identification without the need for the user to present any document or boarding pass.
Total Security
In the pilot project, indicators such as queue time reduction, access to the departure hall and aircraft are measured, in addition to operating costs. With the tests, it is expected that airport security increases, as facial recognition allows an accurate identification of passengers.
"We are moving towards a fully secure biometric boarding at every airport in the country. In addition to the process being safe from the sanitary point of view, by eliminating the handling of papers during the pandemic, it guarantees the total protection of users' data, because the Embarque + Seguro 100% Digital Boarding System meets all the precepts of the LGPD", says Marcelo Sampaio.
Partnerships
Serpro is MInfra’s strategic partner in the country's transportation digital agenda, but Embarque + Seguro also has the collaboration of airlines and airports where the tests have been carried out, which has enabled the improvement of the project at each stage. The air shuttle pilot test is being implemented with the support of Infraero and Azul Linhas Aéreas; and the technology of facial identification stations was developed by Digicon, IDEMIA and Azul/Pacer companies.
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated, and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com
/ Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
